

One duplicate copy of this form is enclosed.

2. ☒ Specification
46 page(s) of specification; 9 page(s) of claims, 1 page(s) of abstract
3. ☒ Drawings
Formal Figure(s) 1A-19 on 20 sheet(s)
4. ☒ Oath or Declaration
☒ Newly executed
☐ Copy from a prior application (see 37 C.F.R. § 1.63(d))
Deletion of Inventor(s) (in continuation or divisional applications):
☐ Delete the following inventor(s) named in the prior non-provisional application:

☐ The inventor(s) to be deleted are set forth on a signed sheet attached hereto.
5. ☐ The entire disclosure of the prior application referred to above is considered to be part of the accompanying application and is hereby incorporated by reference herein.
6. ☐ Microfiche Computer Program (Appendix)
7. ☐ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
☐ Computer Readable copy
☐ Paper Copy (identical to computer copy)
☐ Statement verifying identity of above copies
8. ☒ Assignment Papers
9. Power of Attorney
☒ Is attached.
☐ The power of attorney appears in the original papers of the prior application.
☐ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
10. ☐ Information Disclosure Statement (IDS)
☐ Copies of IDS Citations
11. Amendments
☐ A preliminary amendment is enclosed.
☐ Cancel in this application claim(s) _____ before calculating the filing fee. At least one independent claim is retained for filing purposes.
☐ Amend the specification by inserting before the first line the sentence: _____.
12. ☒ Return Receipt Postcard
13. Small Entity Status
☐ A small entity statement is enclosed.
☐ A small entity statement was filed in the prior non-provisional application and such status is still proper and desired.
☐ Is no longer claimed.
14. ☐ Priority of foreign application number _____, filed on _____ in _____ is claimed under 35 U.S.C. § 119(a)-(d)
15. ☐ Petition under 37 C.F.R. § 136 for Extension of Time
16. ☐ Other: _____

Address all future correspondence to:

Jeffrey C. Hood
Conley, Rose, & Tayon, P.C.
P.O. Box 398
Austin, Texas 78767
Phone: (512) 476-1400 Fax: (512) 703-1250

Signature

Name

Registration No.

Date

Jeffrey C. Hood

35,198

12/20/2000

jc808 U.S. PTO
09/742510
12/20/00

[illegible]

Subramanian Ramamoorthy, Lothar Wenzel, Greg Morrow, Mike Santori, John Limroth, Ram Kudukoli and Robert Dye

ss ss ss ss

CERTIFICATE OF EXPRESS MAIL
UNDER 37 C.F.R. §1.10

"Express Mail" mailing label number. EL675026847US
DATE OF DEPOSIT: December 20, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231


Derrick Brown

Demographic characteristics		Clinical characteristics		Treatment characteristics		Outcome characteristics	
Variable	Value	Variable	Value	Variable	Value	Variable	Value
Age (years)	65.2	Sex (male/female)	10/10	Time to treatment (days)	12.5	Time to outcome (days)	15.2
Weight (kg)	78.5	Comorbidities	15	Time to death (days)	18.7	Time to hospitalization (days)	20.1
Height (cm)	175.3	Medications	20	Time to discharge (days)	22.3	Time to readmission (days)	25.4
BMI (kg/m ²)	25.8	Smoking status	10	Time to surgery (days)	24.6	Time to death (days)	28.9
SBP (mmHg)	135.2	Alcohol consumption	15	Time to death (days)	30.1	Time to death (days)	32.5
DBP (mmHg)	85.1	Family history	10	Time to death (days)	35.2	Time to death (days)	38.7
Heart rate (b/min)	72.5	Genetic factors	15	Time to death (days)	40.3	Time to death (days)	42.8
Cholesterol (mmol/L)	5.2	Environmental factors	10	Time to death (days)	45.4	Time to death (days)	47.9
Glucose (mmol/L)	5.8	Social factors	15	Time to death (days)	50.5	Time to death (days)	52.9
HbA1c (%)	6.5	Occupational factors	10	Time to death (days)	55.6	Time to death (days)	58.0
Hemoglobin (g/L)	13.2	Marital status	15	Time to death (days)	60.7	Time to death (days)	63.1
Platelets (x10 ⁹ /L)	215.3	Education level	10	Time to death (days)	65.8	Time to death (days)	68.2
White blood cells (x10 ⁹ /L)	11.5	Income level	15	Time to death (days)	70.9	Time to death (days)	73.3
Neutrophils (%)	78.2	Health insurance	10	Time to death (days)	76.0	Time to death (days)	78.4
Lymphocytes (%)	18.5	Insurance type	15	Time to death (days)	81.1	Time to death (days)	83.5
Monocytes (%)	2.3	Insurance status	10	Time to death (days)	86.2	Time to death (days)	88.6
Eosinophils (%)	0.8	Insurance coverage	15	Time to death (days)	91.3	Time to death (days)	93.7
Basophils (%)	0.2	Insurance type	10	Time to death (days)	96.4	Time to death (days)	98.8
Prothrombin time (s)	14.5	Insurance status	15	Time to death (days)	101.5	Time to death (days)	103.9
Partial thromboplastin time (s)	32.1	Insurance coverage	10	Time to death (days)	106.6	Time to death (days)	109.0
Fibrinogen (g/L)	4.2	Insurance type	15	Time to death (days)	111.7	Time to death (days)	114.1
D-dimer (ng/mL)	0.5	Insurance status	10	Time to death (days)	116.8	Time to death (days)	119.2
C-reactive protein (mg/L)	10.2	Insurance coverage	15	Time to death (days)	121.9	Time to death (days)	124.3
Erythrocyte sedimentation rate (mm/h)	25.3	Insurance type	10	Time to death (days)	127.0	Time to death (days)	129.4
Interleukin-6 (pg/mL)	15.2	Insurance status	15	Time to death (days)	132.1	Time to death (days)	134.5
Tumor necrosis factor-α (pg/mL)	8.7	Insurance coverage	10	Time to death (days)	137.2	Time to death (days)	139.6
Interleukin-1β (pg/mL)	4.5	Insurance type	15	Time to death (days)	142.3	Time to death (days)	144.7
Interleukin-10 (pg/mL)	2.3	Insurance status	10	Time to death (days)	147.4	Time to death (days)	149.8
Interleukin-18 (pg/mL)	1.2	Insurance coverage	15	Time to death (days)	152.5	Time to death (days)	154.9
Interleukin-27 (pg/mL)	0.8	Insurance type	10	Time to death (days)	157.6	Time to death (days)	160.0
Interleukin-36 (pg/mL)	0.5	Insurance status	15	Time to death (days)	162.7	Time to death (days)	165.1
Interleukin-37 (pg/mL)	0.3	Insurance coverage	10	Time to death (days)	167.8	Time to death (days)	170.2
Interleukin-38 (pg/mL)	0.2	Insurance type	15	Time to death (days)	172.9	Time to death (days)	175.3
Interleukin-39 (pg/mL)	0.1	Insurance status	10	Time to death (days)	178.0	Time to death (days)	180.4
Interleukin-40 (pg/mL)	0.1	Insurance coverage	15	Time to death (days)	183.1	Time to death (days)	185.5
Interleukin-41 (pg/mL)	0.1	Insurance type	10	Time to death (days)	188.2	Time to death (days)	190.6
Interleukin-42 (pg/mL)	0.1	Insurance status	15	Time to death (days)	193.3	Time to death (days)	195.7
Interleukin-43 (pg/mL)	0.1	Insurance coverage	10	Time to death (days)	198.4	Time to death (days)	200.8
Interleukin-44 (pg/mL)	0.1	Insurance type	15	Time to death (days)	203.5	Time to death (days)	205.9
Interleukin-45 (pg/mL)	0.1	Insurance status	10	Time to death (days)	208.6	Time to death (days)	211.0
Interleukin-46 (pg/mL)	0.1	Insurance coverage	15	Time to death (days)	213.7	Time to death (days)	216.1
Interleukin-47 (pg/mL)	0.1	Insurance type	10	Time to death (days)	218.8	Time to death (days)	221.2
Interleukin-48 (pg/mL)	0.1	Insurance status	15	Time to death (days)	223.9	Time to death (days)	226.3
Interleukin-49 (pg/mL)	0.1	Insurance coverage	10	Time to death (days)	229.0	Time to death (days)	231.4
Interleukin-50							

Jeffrey C. Hood
Reg. No. 35,198
ATTORNEY FOR APPLICANT(S)